医学
肺栓塞
优势比
置信区间
入射(几何)
前交叉韧带
静脉血栓形成
队列
风险因素
外科
深静脉
前交叉韧带重建术
队列研究
血栓形成
内科学
物理
光学
作者
Jesper Kraus Schmitz,Viktor Lindgren,P-M Janarv,Magnus Forssblad,Anders Stålman
出处
期刊:The bone & joint journal
[British Editorial Society of Bone & Joint Surgery]
日期:2019-01-01
卷期号:101-B (1): 34-40
被引量:32
标识
DOI:10.1302/0301-620x.101b1.bjj-2018-0646.r1
摘要
Aims The aim of this study was to investigate the incidence, risk factors, and outcome of venous thromboembolism (VTE) following anterior cruciate ligament (ACL) reconstruction in a nationwide cohort. Patients and Methods All ACL reconstructions, primary and revision, that were recorded in the Swedish Knee Ligament Register (SKLR) between 2006 and 2013 were linked with data from the Swedish National Board of Health and Welfare. The incidence of VTE was determined by entries between the day of surgery until 90 days postoperatively based on diagnosis codes and the prescription of anticoagulants. Risk factors, outcome, and the use of thromboprophylaxis were analyzed. Descriptive statistics with multivariate analysis were used to describe the findings. Results The cohort consisted of 26 014 primary and revision ACL reconstructions. There were 89 deep venous thromboses (DVTs) and 12 pulmonary emboli (PEs) with a total of 95 VTEs (0.4 %). Six patients with a PE had a simultaneous DVT. The only independent risk factor for VTE was age greater than or equal to 40 years (odds ratio 2.31, 95% confidence interval 1.45 to 3.70; p < 0.001). Thromboprophylaxis was prescribed to 9461 patients (36%) and was equally distributed between those with and those without a VTE (37.9% vs 36.4%). All patient-reported outcome measures (PROMs) one and two years postoperatively were significantly lower in those with VTE. Conclusion The incidence of VTE following ACL reconstruction is 0.4%, and the only significant risk factor is age. Patients with VTE had worse postoperative clinical outcome than patients without VTE. We recommend against the routine use of thromboprophylaxis, but it should be considered in older patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI